Merck reported strong first-quarter results with sales and non-GAAP EPS exceeding expectations, demonstrating robust growth across key business segments. Management maintained optimistic guidance and highlighted strategic investments in growth drivers and pipeline advancements, which can bolster investor confidence in the short term.

[1]